Nanologica AB (OSTO:NICA) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NICA Nanologica AB OSTO:NICA
46 GF Score
Price kr0.32
GF Value kr2.94
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Nanologica AB Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nanologica AB  (OSTO:NICA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Nanologica AB Cyclically Adjusted PS Ratio Related Terms


Nanologica AB Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Nanologica AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanologica AB Cyclically Adjusted PS Ratio Chart

Nanologica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 15.00 16.71 3.19 1.79

Nanologica AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.35 2.38 1.71 0.84 1.02

OSTO:NICA vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Nanologica AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanologica AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanologica AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nanologica AB's Cyclically Adjusted PS Ratio falls into.


OSTO:NICA
46GF Score
Nanologica AB OSTO:NICA
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanologica AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Nanologica AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Nanologica AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.083/134.6100*134.6100
=0.083

Current CPI (Jun. 2026) = 134.6100.

Nanologica AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.120 101.138 0.160
201612 0.312 102.022 0.412
201703 0.002 102.022 0.003
201706 0.000 102.752 0.000
201709 0.038 103.279 0.050
201712 0.475 103.793 0.616
201803 0.083 103.962 0.107
201806 0.034 104.875 0.044
201809 0.061 105.679 0.078
201812 0.130 105.912 0.165
201903 0.129 105.886 0.164
201906 0.169 106.742 0.213
201909 0.114 107.214 0.143
201912 0.156 107.766 0.195
202003 0.208 106.563 0.263
202006 0.174 107.498 0.218
202009 0.071 107.635 0.089
202012 0.208 108.296 0.259
202103 0.192 108.360 0.239
202106 0.153 108.928 0.189
202109 0.071 110.338 0.087
202112 0.023 112.486 0.028
202203 0.009 114.825 0.011
202206 0.007 118.384 0.008
202209 0.013 122.296 0.014
202212 0.018 126.365 0.019
202303 0.009 127.042 0.010
202306 0.018 129.407 0.019
202309 0.009 130.224 0.009
202312 0.002 131.912 0.002
202403 0.109 132.205 0.111
202406 0.047 132.716 0.048
202409 0.014 132.304 0.014
202412 0.090 132.987 0.091
202503 0.121 132.825 0.123
202506 0.026 133.699 0.026
202509 0.032 133.480 0.032
202512 0.058 133.380 0.059
202603 0.237 133.550 0.239
202606 0.083 134.610 0.083

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Nanologica AB (OSTO:NICA) Overvalued in 2026?

Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued. The current stock price of kr0.32 is trading 89.1% below its estimated GF Value™ of kr2.94. GuruFocus considers Nanologica AB to be Possible Value Trap.

Key valuation signals for OSTO:NICA:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: kr2.94 vs. price of kr0.32 (89.1% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the OSTO:NICA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nanologica AB Business Description

Other Exchanges 4YD:Germany
Address Forskargatan 20 G, Sodertalje, SWE, 151 36
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
46GF Score

Get the complete analysis for OSTO:NICA

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.32
Price
kr2.94
GF Value